Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag in Primary Immune Thrombocytopenia (ESTIT)
NCT02402998Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Feb 2016
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eltrombopag in primary immune thrombocytopenia (ITP), sponsored by GIMEMA. Started Feb 2016; status: completed.
02
Drugs
eltrombopag
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT02402998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02402998.